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*CPT: Pharmacometrics & Systems Pharmacology* (CPT:PSP) is an official open access journal of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).

*CPT: Pharmacometrics & Systems Pharmacology* is a cross-disciplinary journal devoted to publishing advances in quantitative (e.g., modeling and simulation) methods as applied in pharmacology, physiology and therapeutics in humans. The journal welcomes original research articles, reviews and tutorials that bridge the following areas: pharmacometrics, modeling and simulation as applied to the design and evaluation of clinical trials, systems pharmacology modeling, particularly with a mechanistic link to human (patho)physiology, disease modeling, "population" or mixed-effects pharmacokinetics and pharmacodynamics (PKPD) modeling, modeling and simulation to support translational research, physiologically-based pharmacokinetics (PBPK), modelbased meta-analyses of clinical trials, mechanism-based pharmacokinetic-pharmacodynamic modeling, computational pharmacology, bioinformatics, comparative efficacy, effectiveness and cost-effectiveness. Systems pharmacology may involve the application of systems biology approaches to study drug activities, targets and effects. The discipline is often defined with reference to engineering and pharmacological principles as the quantitative analysis of the dynamic interactions between drugs and a biologic system that aims to understand the behavior of the system as a whole. The common focus will be on quantitativemethods that improve our understanding of pharmacology and therapeutics in humans.
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